EORTC Leukemia Group is mainly concerned with improving the outcome of adult patients with leukemias or related haematological malignancies. We operate through clinical trials, such as large standard-practice changing phase III studies, and run strong translational research programmes analysing epigenetic therapy in acute myeloid leukemia or myelodysplastic syndrome. EORTC works in collaboration with other national and international study groups, particularly the GIMEMA. We are also developing robust survivorship studies, taking advantage of the large number of patients already included in phase III research.
Related NewsAll news
Found that first-line monotherapy with low-dose Gemtuzumab Ozogamicin, as compared with Best Supportive Care, significantly improved OS in older AML patients who were ineligible for intensive chemotherapy.
Demonstrated decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL.
- RP-1479 (SPARTA): The Survivorship Project to understand and to improve long-Term outcomes for Acute myeloid leukemia patients.
(Project leaders: F. Efficace / F. Baron) The research project is ongoing.
IMI2 HARMONY – Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY. This project will gather, integrate and analyse anonymous patient data from a number of sources. The project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others. (No website available yet)
Vilnius University Hospital Santariskiu Santaros Clinics Klinikos